Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.

Incorporating CD40 ligand (CD40L) into vaccine strategies has shown considerable potential for enhancing immune responses. In this study, we designed and formulated a CD40L-based multi-epitope vaccine construct using immunoinformatics approaches, and compared it to a full-length CD40L-based vaccine construct. The study commenced with the identification and screening of potential T-cell and B-cell epitopes derived from the CD40L protein, followed by the construction of a multi-epitope vaccine from these selected epitopes. We analyzed and validated the physicochemical and structural properties of the vaccine constructs. Further, we predicted disulfide bonds, performed protein-protein docking, and conducted molecular dynamics simulations to evaluate the constructs. Comparative analyses of the ligand-binding site localization were conducted using LigPlot. Additionally, simulation trajectories were analyzed using multiple descriptors, including root mean square deviations, radius of gyration, and root mean square fluctuations. Our findings indicated that the CD40L multi-epitope vaccine construct possessed favorable physicochemical properties and a validated structural profile. Immune simulation studies showed a stronger affinity of the multi-epitope construct for the CD40 receptor compared to the full-length CD40L construct. Overall, the CD40L multi-epitope vaccine construct demonstrated greater potency in eliciting an effective immune response than the full-length CD40L construct. These results highlight a promising approach to vaccine design for the prevention or treatment of infections and cancers.